Valued at almost $6bn in the seven major markets in 2011 (US, Japan, France, Germany, Italy, Spain, and the UK), the Alzheimer’s disease drug market is forecast to experience double-digit growth to 2020. The catalysts for this include an aging population, earlier and improved diagnosis, and the introduction of immunotherapies that will be prescribed in addition to existing treatments.
Recent front page articles in popular magazine such as Barron’s and American Profile highlight the importance of work on Alzheimer’s Disease by dedicated firms that range in size from Anavex Life Sciences (OTC: AVXL) to major pharmaceutical giants such as Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY)
The articles below present interesting news and developments in the field.
USA Today “Alzhemier’s Mistaken Diagnosis”
Time “New Drug Trial Aims To Prevent Alzheimer’s Before It Starts”
MPR “Researcher gets govt. investment for Alzheimer’s treatment technique” http://minnesota.publicradio.org/display/web/2012/05/16/alzheimers-treatment-technique/